Nihon Kohden Corp
TSE:6849
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TVS Motor Company Ltd
NSE:TVSMOTOR
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (10.5), the stock would be worth ¥1 709.12 (18% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.9 | ¥1 448 |
0%
|
| 3-Year Average | 10.5 | ¥1 709.12 |
+18%
|
| 5-Year Average | 4.4 | ¥718.01 |
-50%
|
| Industry Average | 8.3 | ¥1 345.46 |
-7%
|
| Country Average | 8.7 | ¥1 407.71 |
-3%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥258.9B
|
/ |
Jan 2026
¥24.3B
|
= |
|
|
¥258.9B
|
/ |
Mar 2026
¥26.1B
|
= |
|
|
¥258.9B
|
/ |
Mar 2027
¥29.4B
|
= |
|
|
¥258.9B
|
/ |
Mar 2028
¥32.1B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Nihon Kohden Corp
TSE:6849
|
235.1B JPY | 8.9 | 19 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
159.2B USD | 13.8 | 25.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.7B USD | 45.6 | 60.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126B USD | 19.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.8B USD | 12.9 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
96.2B USD | 19.7 | 33.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.6B EUR | 10.9 | 19.4 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 24 | 44.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.1B USD | 30.8 | 43.5 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.3B USD | 10 | 25.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.5B USD | 11.3 | 15.6 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 6.7 |
| Median | 8.7 |
| 70th Percentile | 12.2 |
| Max | 214 699 781.2 |
Other Multiples
Nihon Kohden Corp
Glance View
Nihon Kohden Corp., founded in 1951, has evolved into a pioneering force in the medical technology landscape, blending innovation with a storied heritage. This Tokyo-based firm established its foothold by developing advanced medical electronic devices, initially focusing on EEG (electroencephalography) machines. As medical science rapidly advanced, Nihon Kohden expanded its portfolio to include a range of diagnostic and monitoring equipment. Today, the company's product line encompasses patient monitors, defibrillators, electrocardiographs, and clinical information systems, serving various healthcare domains. This focus on critical care and diagnostics creates consistent demand across global hospitals and clinics, reinforcing its reputation as a dependable partner in medical excellence. Financially, Nihon Kohden's business model thrives on a dual revenue structure: product sales and after-sales service. By manufacturing and distributing complex equipment directly and through a network of distributors, the company captures a significant share of initial capital expenditure in healthcare institutions. Furthermore, it enhances this income by offering ongoing equipment maintenance, training, and customer support, forming long-term relationships with healthcare providers. These services ensure not only a steady revenue stream beyond the initial sale but also brand loyalty and trust in an industry where precision and reliability are paramount. As it continues to innovate, Nihon Kohden's commitment to addressing the evolving needs of healthcare practitioners fortifies its market position and operational success.